Evotec and Almirall are using a novel approach to disrupt cell signaling to discover and develop first-in-class therapeutics targeting dermatology diseases.
BioIVT’s research on the mechanisms underlying the C-DILI assay introduces “a new paradigm,” which suggests BSEP inhibition alone will not lead to bile acid-induced liver injury, says study director.
The biopharmaceutical analytical and bioanalytical contract solutions provider SGS is investing more than $1.7m to expand its North American biopharmaceutical testing capabilities.
The Nuvisan Group is taking on part of Galderma’s R&D capacities site, growing its service lines in bioanalysis, clinical trial supplies, and pharmaceutical analytics
This month marked the effective start date for Parexel's new executive VP and CFO Greg Rush, who joins August's People on the Move with several other c-suite hires, including a new CEO at Citoxlab and COO at ProSciento.
IRBM and Merck have signed a new agreement in the peptide therapeutics area through which the Italian CRO will identify potential peptide leads for a specific Merck target.
The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.
The contract services provider is now collecting and using peripheral blood mononuclear cells (PBMCs) for early phase clinical trials at its Antwerp, Belgium-based Clinical Pharmacology Unit (CPU).
IIVS is collaborating with global laboratories to validate an improved skin sensitization reactivity method to meet toxicology and regulatory requirements.
Science Exchange has partnered with Taconic Biosciences, a supplier of genetically engineered rodent models to offer access to Taconic’s portfolio including the company’s Easi-CRISPR technology.
The joint drug discovery project announced yesterday will combine Centogene’s genetic testing service offerings with Evotec's iPSC platform and drug discovery capabilities.
Fusion Antibodies revenue grew 41% in FY2018, and while “pop up consultants” have created new competition, the CRO is differentiating itself by investing in its services and focusing on quality.
The multi-phase collaboration between WuXi AppTec Research Service Division and Cyclica looks to advance polypharmacology in drug discovery using AI-augmented technology.
Altasciences is set to acquire SNBL in a deal that looks to bridge the gap between preclinical and proof of concept studies – and provide an average of 25% time savings, says CEO.
Alpha Genesis is exploring blockchain technology applications in its primate research activities – the use of which aims to boost transparency and traceability across several areas of the business.
Sygnature Discovery is adding a new facility at Alderley Park in Cheshire, UK in response to an increasing demand for outsourced preclinical research services.
Fueled by increasing investments from biotech, Charles River expects to double the size of its business over the next five years – organically and through M&A – to become a ‘more responsive partner,’ says CEO.
Evotec is conducting preclinical and toxicology/safety studies for Stealth BioTherapeutics’ lead candidate, ahead of clinical trials slated to begin in 2019.
The UK-based CRO anticipates that its FY19 earnings results will be “significantly behind current market expectations,” due to increasing competition and pricing pressures.
Outsourcing-Pharma recently conducted a second ‘state of the industry’ survey to gauge views about the current state of the global pharmaceutical outsourcing market and the evolving relationships of those involved.
The global market for in vitro toxicity testing is predicted to reach $8.8bn by 2023 – and demand is expected to increase, driven by new technologies and regulations, says Charles River.
The multi-year project with an unnamed pharmaceutical company will use the macaque monkey as a developmental model for progressive brain disorders and is valued at more than $1m.
Sutro Biopharma and Merck have signed a collaboration and licensing agreement, which will leverage Sutro's proprietary cell-free protein synthesis and site-specific conjugation platforms.
Antoxerene and investor firm Juvenescence have collaborated to form FoxBio Inc., an offshoot focused on small molecule drug discovery for the pathways of ageing.
Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.
BASi and Seventh Wave Laboratories are joining operations via an asset purchase agreement, through which BASi will lease the CRO's facility in Maryland Heights, MO.
BioIVT adds transporter assay products and services to its ADME-Toxicology portfolio with the acquisition of Optivia Biotechnology – a deal which aligns with the company’s efforts to support drug safety and efficacy, says VP.
Emulate is further developing its Human Emulation System and building a team of experts to help drive broad adoption of its Human Emulation System in the pharmaceutical industry.
The contract bioanalytical testing services company BioAgilytix is expanding its technology suite with the addition of Sword Bio’s detection platform for immunoassays.
Evotec is integrating Sanofi’s infectious disease unit into its organization and will collaborate to launch new "open innovation" initiatives aimed at accelerating infectious disease research.
Medidata is acquiring Shyft Analytics for $195m, creating a new platform that will combine clinical development with commercial and real-world data analytics in a first for the industry, says a company executive.
Wasdell Group is investing £500k ($669k) in a new laboratory as the first phase of an expansion strategy, which includes a similar investment in Ireland "to cater for all situations after Brexit," says managing director.
Following on from the success of last year's survey, Outsourcing-Pharma is running another 'state of the industry' survey to gauge views about the current state of the pharmaceutical contract services industry.
